Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03664635 | MB-CART20.1 Lymphoma | completed | Phase 1 / Phase 2 | 10 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05896774 | A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China | completed | Phase 1 | 10 | PfizerINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02268851 |
| A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL |
| completed |
| Phase 1 |
| 45 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Nov 15, 2024 |
| clinicaltrials |
| NCT04840875 | Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma | completed | Phase 1 | 16 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT01857115 | Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)(wCCyd) | completed | Phase 1 / Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02043847 | TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)(BMT-03) | completed | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02924402 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | completed | Phase 1 | 154 | Xencor, Inc.INDUSTRY | 4 | Nov 13, 2024 | clinicaltrials |
| NCT05269940 | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 40 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | completed | Phase 1 | 20 | Noah MerinOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT01755975 | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05567887 | A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies | completed | Phase 1 | 7 | PfizerINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03399539 | Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma | completed | Phase 1 | 8 | Mayo ClinicOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04398485 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 23 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03586999 | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | completed | Phase 1 / Phase 2 | 18 | University of Colorado, DenverOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | completed | Phase 1 | 78 | Sanjay MohanOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03340766 | Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)(HARBOUR) | completed | Phase 1 | 31 | AmgenINDUSTRY | 6 | Oct 17, 2024 | clinicaltrials |
| NCT02927964 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | completed | Phase 1 / Phase 2 | 21 | Robert LowskyOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT03989466 | Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04798586 | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | completed | Phase 1 | 4 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02939183 | Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma(INTREPID-1) | completed | Phase 1 | 61 | AmgenINDUSTRY | 4 | Sep 26, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04500587 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | completed | Phase 1 | 39 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT04274738 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 2 | Aug 27, 2024 | clinicaltrials |
| NCT03829020 | Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Mayo ClinicOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04450069 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | completed | Phase 1 | 18 | Calibr, a division of Scripps ResearchOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT00487305 | Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02192021 | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)(MNA-D) | completed | Phase 1 | 20 | Falo, Louis, MDOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 / Phase 2 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06527781 | A Study of PD5K3 in Healthy Adult Volunteers | completed | Phase 1 | 28 | Chongqing Peg-Bio Biopharm Co., Ltd.INDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02148913 | Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma | completed | Phase 1 | 18 | Corewell Health WestOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04394650 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 78 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 | clinicaltrials |
| NCT04555811 | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | completed | Phase 1 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04434469 | A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 27 | Genentech, Inc.INDUSTRY | 4 | Jul 3, 2024 | clinicaltrials |
| NCT05679258 | A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects | completed | Phase 1 | 172 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02631044 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | completed | Phase 1 | 387 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT03309111 | Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 81 | Ichnos Sciences SAINDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT04279405 | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | completed | Phase 1 | 43 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03061188 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | completed | Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | completed | Phase 1 | 70 | Sutro Biopharma, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2024source: clinicaltrials